#USA #Fremont #Alamar Biosciences #biomarker assays #NULISAqpcr™

Alamar Biosciences Unveils NULISAqpcr™ Custom Assay Development Kit

Alamar Biosciences, a pioneering force in precision proteomics, has just announced the launch of its innovative NULISAqpcr™ Custom Assay Development Kit. This remarkable product is designed to empower researchers in creating highly sensitive and accurate biomarker assays specifically tailored to their unique research requirements. With this launch, Alamar is making a significant impact on the broader biomarker research community by extending the application of its renowned NULISA™ technology.

Setting a New Standard in Proteomics

The NULISA™ Platform is already recognized for its unprecedented attomolar sensitivity and capability for biomarker detection and quantification. The introduction of the NULISAqpcr Custom Assay Development Kit takes this technology even further. Researchers can now harness their own antibodies to develop customized assays, thereby achieving exceptional sensitivity and reproducibility across various applications, including immunology and neurology.

This customizable kit provides unmatched flexibility, paving the way for a seamless workflow from antibody conjugation to automated NULISAqpcr with the ARGO™ HT instrument. This represents a new benchmark for homebrew single-plex assay development, catering to the growing needs of the scientific community.

Meeting the Demand for Precision

Dr. Yuling Luo, Founder, Chairman, and CEO of Alamar Biosciences, highlighted that this launch is a direct response to researchers' increasing demands for advanced NULISA technology. He stated, “The Custom Assay Development Kit is a direct response to the growing demand from researchers eager to harness our cutting-edge NULISA technology to develop high-performance biomarker assays for translational and clinical research.” This initiative marks a significant milestone in Alamar’s mission to create a transformative ecosystem that fosters precision proteomics.

A Commitment to Innovation

Through the NULISAqpcr Custom Assay Development Kit, Alamar demonstrates its ongoing commitment to innovation and support for the scientific community. This kit is designed to facilitate high-performance research, ensuring that scientists have the tools they need to push the boundaries of biomarker exploration.

Availability

The NULISAqpcr Custom Assay Development Kit is available for order, with shipments set to commence in the second quarter of this year. As a privately held life sciences company, Alamar Biosciences continues to lead the way in powering precision proteomics, which is essential for the early detection of diseases.

NULISA™ Platform and ARGO™ HT System

Alamar's proprietary NULISA™ Platform, integrated with the ARGO™ HT System, represents a breakthrough in biomarker testing, achieving single-digit attomolar detection sensitivity. This capability considerably outperforms existing protein detection technologies on the market, further establishing Alamar as a leader in the field. For more information about Alamar Biosciences and its offerings, visit alamarbio.com.

As the landscape of clinical research evolves, tools like the NULISAqpcr Custom Assay Development Kit will play a vital role in advancing biomarker discovery and enhancing overall research efficacy. With a steadfast commitment to delivering innovative solutions, Alamar Biosciences is set to shape the future of precision proteomics.